Unveiling Trial Related Considerations For Late-Stage Development Of Incretin-Based Therapies
Time: 9:00 am
day: Conference Day Two
Details:
- Leveraging experience in the field and with phase 3 incretin trials at Lilly to explore latestage obesity drug development
- Investigating patient safety in trials which are driving the standard of care
- Driving forward innovation in obesity trials
